Predictors for AKI
The Kaplan–Meier analysis revealed that a higher eGFR (HR: 1.02
[1.00–1.04]) and blood eosinophil count >350/μL (HR:
4.3 [1.21–15.25]) were associated with a higher risk of AKI during
anti-TB treatment. Other risk factors, such as BMI, smoking status,
hypertension, diabetes mellitus, mycobacterial culture results (a
positive AFB smear or positive TB culture), other baseline laboratory
data, and treatment-related side effects, were not statistically
significant (Table 4).
The multivariate Cox regression analysis revealed that older age (HR:
1.06 [1.02–1.11]), a higher baseline eGFR (HR: 1.04
[1.02–1.06] per unit increase in eGFR), and a blood eosinophil
count >350 (109/L) (HR: 10.99
[1.28–53.02]) were significant predictors for AKI development
during anti-TB treatment (Table 4).